Transcode Therapeutics, Inc.
RNAZ· Nasdaq
RNAZTranscode Therapeutics, Inc.
Filed Aug 14, 2023 · 10-Q · 45 days after period end · 0001410578-23-001892
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Net Income | -$4.34M | -$4.67M | $2.77M | -$127.20K |
| EPS Diluted | -$142.38 | -$7.20 | $0.51 | -$0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Transcode Therapeutics, Inc. · CIK 1829635 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end
